5-APB
Template:Proofread |
|
5-APB (5-(2-aminopropyl)benzofuran) is a stimulant and entactogenic drug of the phenethylamine and benzofuran class. 5-APB is sometimes called Benzo Fury, although this name is also used for 6-APB as well.
5-APB | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemical Nomenclature | |||||||||||||||||||||||||||||||||
Common names | 5-APB | ||||||||||||||||||||||||||||||||
Substitutive name | 5-(2-Aminopropyl)benzofuran | ||||||||||||||||||||||||||||||||
Systematic name | 1-(Benzofuran-5-yl)-propan-2-amine | ||||||||||||||||||||||||||||||||
Class Membership | |||||||||||||||||||||||||||||||||
Psychoactive class | Entactogen / Stimulant | ||||||||||||||||||||||||||||||||
Chemical class | Amphetamine / Benzofuran | ||||||||||||||||||||||||||||||||
Routes of Administration | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||||||||||
MAOIs | |||||||||||||||||||||||||||||||||
Serotonin releasers | |||||||||||||||||||||||||||||||||
SSRIs | |||||||||||||||||||||||||||||||||
5-HTP |
Research on benzofurans was originally carried out by David Nichols and his team at Purdue, where they synthesized 5-APDB (the dihydrofuran analogue) around 1993.
It wasnt until 2006, however, that the pharmaceutical company Eli Lilly and Co. had their patent for this compound granted, having originally filed it in 2006.Oddly enough, none of Nichols' work was mentioned in the patent.
Chemistry
5-APB is a benzofuran and phenethylamine, so there is the ethylamine chain attached to the 2 position of the ring. It can also classify as an amphetamine deriviative, because the ethylamine chain is alpha methylated. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. The oxygen in the furan ring is placed at the 5 position, which generally constitutes more stimulating effects than when the oxygen is placed at the 6 position, which is usually described as being more psychedelic in effects.
Pharmacology
5-APB is a triple reuptake inhibitor(TRI) with Ki values of 180, 265 and 811 nM for NET, DAT and SERT respectively, as well as being an agonist for the 5-HT2A and 5-HT2B receptors (Ki of 14nM at 5-HT2B). It has also been speculated from the structure activity relationship(SAR) that 5-APB is a monoamine releasing agent.[1]
Toxicity and harm potential
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] & "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - 25x compounds are highly stimulating and physically straining. Combinations with 5-APB should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
- "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
- "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
- "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
- "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
- "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - 5-APB may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
- "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is known to lower the seizure threshold[2] and combinations with stimulants may further increase this risk.
- "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.[3]
- Stimulants - The neurotoxic effects of 5-APB may be increased when combined with other stimulants.
- Cocaine - This combination may increase strain on the heart.
Serotonin syndrome risk
Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.
- MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.[4]
- Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
- SSRIs - Such as citalopram and sertraline
- [[Wikipedia:SNRIs|DangerousInteraction::SNRIs]] - Such as tramadol and venlafaxine
- 5-HTP
Legal issues
- UK: 5-APB is a Class B drug.
- USA: Could be considered an analogue of MDA, therefore would be covered under the Federal Analogue Act if intended for human consumption.
See also
External links
- 5-APB(Tripsit)
- 5-APB(Wikipedia)
- 5-APB experiences(Erowid)
- The Big and Dandy 5-APB Thread(Bluelight)
References
- ↑ https://en.wikipedia.org/wiki/5-APB
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183.
- ↑ Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.
- ↑ Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.